ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer. - Wikidata - awgldk - TriplyDB

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

http://www.wikidata.org/entity/Q35548439

about

Multiple gene aberrations and breast cancer: lessons from super-responders.A Review of Fulvestrant in Breast Cancer.Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance.

P2860

Q35645466-69CE1297-8850-4CA4-8113-E119E3641AB1 Q53733893-4ACD0E24-93DA-4E02-B9C1-F52BF9F3D08C Q55496875-487D5006-2E79-4621-8AC1-20D59A456937

P2860

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

http://www.wikidata.org/entity/Q35548439

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

@ast

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

@en

type

label

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

@ast

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

@en

prefLabel

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

@ast

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

@en

P1433

Q35548439-2B4A688C-A803-4B77-9A0E-70246E7546A6

P1476

Q35548439-40D885ED-5F1F-44A1-8F3A-D44539965AAD

P2093

Q35548439-7B7042F1-FADB-486F-A6F2-D5A8382F938E

Q35548439-B25995D0-A138-44C8-85F1-9F0943CB828B

Q35548439-B6EE2C8E-E2CA-473F-AE85-8EBD0827545F

P2860

Q35548439-11974E72-DDD9-4CEE-84A9-BB4CA1303201

Q35548439-1D008F18-5D7D-41E2-8D1F-C5412A9EC700

Q35548439-63A07EE8-B22B-4ED0-A9EA-52A0AE35EA55

Q35548439-6C72FF94-F98F-47F6-9E0D-8A8320323244

Q35548439-6D748EB5-0A00-4A6C-837E-87DE5ACCEACB

Q35548439-95CE45E4-8204-4AB7-AACA-8C28A2078CB7

Q35548439-AD1CCCCB-4E8C-4E89-9C7A-4CADB890C40E

Q35548439-B6C66E90-51DA-47AC-8E1E-31C2AA087298

Q35548439-BC02EB1A-F875-4FD8-9FA3-C135BF34DD15

Q35548439-E5759EDC-2E2D-49EA-B7A9-7CC5AA69268B

P304

Q35548439-2296FDC4-8295-47D4-8500-1F58B612C601

P31

Q35548439-50E89693-EDB9-469F-96E9-91F0F03EF6C9

P356

Q35548439-0DA515A1-83B8-4865-A56F-AEEEEB1932FF

P433

Q35548439-F9B6C156-F7F9-44D5-AC3D-39B5D32F1D17

P478

Q35548439-F39225CA-D35F-4D9F-A378-75AD978E898B

P577

Q35548439-9C3AB904-AD85-42E7-AEA6-349747664B48

P5875

Q35548439-09FC52A0-386F-46A3-8A29-06C0303DC307

P698

Q35548439-A39417AC-E698-4BE0-B392-24CB7C95D0F7

P932

Q35548439-F31E3A61-43BC-4D2F-87B3-CA7FD4A3ECE0

P356

2159-8290.CD-11-0192

P1433

Cancer Discovery

P1476

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

@en

P2093

Brian A Van Tine

http://www.w3.org/2001/XMLSchema#string

Matthew J Ellis

http://www.w3.org/2001/XMLSchema#string

Robert J Crowder

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol.

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.

Estrogen receptor: current understanding of its activation and modulation.

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Fulvestrant revisited: efficacy and safety of the 500-mg dose.

Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.

P304

287-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-11-0192

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51808736

http://www.w3.org/2001/XMLSchema#string

P698

22096658

http://www.w3.org/2001/XMLSchema#string

P932

3215586

http://www.w3.org/2001/XMLSchema#string